# Oxaliplatin in Esophagus Cancer (Advanced) 1st Line

> **NCT00259402** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 41 (actual)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **DRUG:** Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)

## Key facts

- **NCT ID:** NCT00259402
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2009-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259402, "Oxaliplatin in Esophagus Cancer (Advanced) 1st Line". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00259402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*